Insider Buying: Pieris Pharmaceuticals Inc (PIRS) Director Buys $57,500.00 in Stock

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Director James A. Geraghty purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 15th. The shares were bought at an average price of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at $115,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pieris Pharmaceuticals stock traded down $0.01 during midday trading on Friday, hitting $5.92. 313,571 shares of the company’s stock were exchanged, compared to its average volume of 549,466. Pieris Pharmaceuticals Inc has a 12-month low of $3.83 and a 12-month high of $9.75. The company has a market capitalization of $320.07 million, a P/E ratio of -14.80 and a beta of 1.72.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.14). Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. The business had revenue of $4.15 million for the quarter, compared to analysts’ expectations of $11.39 million. sell-side analysts anticipate that Pieris Pharmaceuticals Inc will post -0.48 earnings per share for the current year.

Several research analysts have issued reports on the stock. HC Wainwright set a $12.00 price objective on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. ValuEngine raised shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cowen assumed coverage on shares of Pieris Pharmaceuticals in a research report on Friday, May 4th. They set an “outperform” rating on the stock. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 17th. Finally, Evercore ISI assumed coverage on shares of Pieris Pharmaceuticals in a research report on Monday, March 19th. They set an “outperform” rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $11.50.

A number of institutional investors have recently modified their holdings of PIRS. A.R.T. Advisors LLC purchased a new stake in shares of Pieris Pharmaceuticals in the first quarter valued at about $103,000. Wells Fargo & Company MN purchased a new stake in shares of Pieris Pharmaceuticals in the third quarter valued at about $105,000. Cetera Advisor Networks LLC purchased a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at about $124,000. Alpine Global Management LLC purchased a new stake in shares of Pieris Pharmaceuticals in the first quarter valued at about $136,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Pieris Pharmaceuticals in the first quarter valued at about $141,000. 49.81% of the stock is currently owned by institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply